FIG. 1A



mATG only
rbIgG only
Average anti-mATG IgG titer (x10⁴)
14
12
10
8
6
4
2
0
0
1
2
3
4
5
6
7
8
Weeks

FIG. 1B



mATG
rbIgG
Average anti-rabbit IgG titer (x10⁴)
624
522
420
318
216
114
15
11
7
5
0
0
2
4
6
8
10
12
14
16
18
20
Weeks
mATG/rIgG
treatments

FIG. 2



Average anti-Alemtuzumab IgG titers (x10⁴)
135
110
85
60
35
24
20
16
12
8
4
0
0
2
4
6
8
10
12
14
16
18
20
Weeks
Alemtuzumab treatments

FIG 3



mATG+ MTX
mATGonly
rbIgGonly
Average anti-rabbit IgG titer (x10⁴)
14
12
10
8
6
4
2
0
0
1
2
3
4
5
6
7
8
9
Weeks

FIG. 4A



Average anti-rabbit IgG titer (x10^5)
70
60
50
40
30
20
10
0
mATG
mATG+3MTX
0
1
2
3
4
Months
ATG
3x MTX

FIG. 4B



Average anti-rabbit IgG titer (x10^6)
70
60
50
40
30
20
10
0
mATG
mATG+1MTX
0
1
2
3
4
Months
mATG
1x MTX

FIG. 4C



Average anti-rabbit IgG titer (x10⁵)
70
60
50
40
30
20
10
0.0
0
1
2
3
4
Months
ATG
1x MTX
3x MTX
mATG
mATG+1MTX
mATG+3MTX

FIG. 5



Average anti-rabbit IgG titer (x10⁶)
18
16
14
12
10
8
6
4
2
0
mATG
mATG+1x MTX
mATG+3x MTX
0
1
2
3
4
6
Months
ATG
1x MTX
3x MTX

FIG. 6



mATG
mATG+1 cycle MTX
Average anti-rabbit IgG titer
8,500,000
6,000,000
3,500,000
1,000,000
800,000
550,000
300,000
50,000
25,200
200
0
1
2
3
4
5
6
7
Months
mATG
1x MTX

FIG. 7A




FIG. 7B




FIG. 7C




FIG. 8A.




FIG. 8B.




FIG. 8C.




FIG. 8D.




FIG. 9 A.



Alemtuzumab-specific IgG Titers
2,750,000
2,500,000
2,250,000
2,000,000
1,750,000
1,500,000
1,250,000
1,000,000
750,000
500,000
250,000
0
Alem
Alem + MTX (0.5)
Alem + MTX (1)
Alem + MTX (2)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Weeks
Alemtuzumab
(0.5mg/kg/day, IV)
5
3
3
Methotrexate
7

FIG. 9 B.



Anti-Alemtuzumab IgG Titers
4,000,000
3,000,000
2,000,000
1,000,000
0
Alem
A+M0.5
A+M1
A+M2

FIG. 10



ATG (ug/ml)
mATG
mATG + 1x MTX
Hours post mATG
mATG dose 1
mATG dose 3
mATG dose 5

FIG. 11



Depletion of CD4 Cells
(Blood)
% Change
(compared to before
treatment)
140
120
100
80
60
40
20
0
p<0.01
mATG
mATG +1Mtx
Depletion of CD8 Cells
(Blood)
% Change
(compared to before
treatment)
200
150
100
50
0
P<0.01
mATG
mATG +1Mtx

FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 14



Total circulating T cells
CD3
Absolute cell number / ul
500
400
300
200
100
0
Day -2
Day 1
5th monthly dose
of alemtuzumab
Total circulating B cells
CD19+
Absolute cell number / ul
4000
3000
2000
1000
0
Day -2
Day 1
5th monthly dose
of alemtuzumab
Alemtuzumab
Alemtuzumab + MTX

FIG. 15A




FIG. 15B




FIG. 15C



rhGAA titer GAA KO 1-cycle vs. 3-cycle MTX
Week 6
Week 8
Week 16
Week 18
anti-rhGAA IgG titer(x10³)
1400
1200
1000
8000
600
400
200
0
rhGAA
1-cycle MTX
3-cycle MTX

FIG. 16A




FIG. 16B




FIG. 17



Percent Graft Survival
100
80
60
40
20
0
0
10
20
30
40
50
60
85
110
Day post-transplant
Untreated
mATG
MTX
mATG + 2mg/kg MTX d0-6
mATG + 0.5mg/kg MTX d0-6
mATG + 0.5mg/kg MTX d0-11

FIG. 18A




FIG. 18B




FIG. 18C



Alloantibodies
21 Days Post Transplant
Ratio of alloantibodies to unstained control
60
40
20
0
p=0.0008
p<0.0001
allo-no treatment
mATG
MTX
mATG+ MTX

FIG. 19



B10 numbers in spleen
Cell numbers
800000.0
600000.0
400000.0
200000.0
0.0
p=0.07
p=0.007
p=0.002
p=0.001
saline-day7
rhGAA-day7
rhGAA+MTX-day7
saline-day8
rhGAA-day8
rhGAA+MTX-day8

FIG. 20



CD86+ Transitional 2 B cells
Absolute cell number
5.0×10^5
4.0×10^5
3.0×10^5
2.0×10^5
1.0×10^5
0
MTX
rhGAA
rhGAA+MTX
saline
Day 6
CD86+Transitional 3 B cells
CD86+Follicular B cells
1.2×10^6
1.0×10^6
8.0×10^5
6.0×10^5
4.0×10^5
2.0×10^5
CD86+Marginal zone B cells
300000
200000
100000

FIG. 21



Activated Marginal Zone B cells
Absolute cell number/spleen
7.00E+05
6.00E+05
5.00E+05
4.00E+05
3.00E+05
2.00E+05
1.00E+05
0.00E+00
4 5 6 7 8 11 12 13 14 15
Days
rhGAA
rhGAA+MTX
rhGAA+MTX
Activated Follicular B cells
Absolute cell number/spleen
1.60E+06
1.40E+06
1.20E+06
1.00E+06
8.00E+05
6.00E+05
4.00E+05
2.00E+05
0.00E+00
4 5 6 7 8 11 12 13 14 15
Days
rhGAA
rhGAA+MTX
rhGAA+MTX
Activated Transitional 3 B cells
Absolute cell number/spleen
2.50E+05
2.00E+05
1.50E+05
1.00E+05
5.00E+04
0.00E+00
4 5 6 7 8 11 12 13 14 15
Days
rhGAA
rhGAA+MTX
rhGAA+MTX

FIG. 22



Activated T helper cells
Absolute cell number/spleen
1.60E+06
1.40E+06
1.20E+06
1.00E+06
8.00E+05
6.00E+05
4.00E+05
2.00E+05
0.00E+00
4 5 6 7 8 11 12 13 14 15
Days
rhGAA
rhGAA+MTX
rhGAA+MTX
Activated T cytotoxic cells
Absolute cell number/spleen
3.50E+06
3.00E+06
2.50E+06
2.00E+06
1.50E+06
1.00E+06
5.00E+05
0.00E+00
4 5 6 7 8 11 12 13 14 15
Days
rhGAA
rhGAA+MTX
rhGAA+MTX
Activated T regulatory cells
Absolute cell number/spleen
2.50E+05
2.00E+05
1.50E+05
1.00E+05
5.00E+04
0.00E+00
4 5 6 7 8 11 12 13 14 15
Days
rhGAA
rhGAA+MTX
rhGAA+MTX

FIG. 23



1
2
3
4
5
6
Months
1x MTX
3x MTX
mATG Injections
Methotrexate injections (15min, 24hrs and 48 hrs post mATG injections)
Terminal Sacrifice three days following Month 5 treatment to collect spleens and lymph nodes

FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B





FIG. 26


Spleen - T cells
T cells
CD3+
T helper cells
CD4+
T cytotoxic cells
CD8+
T regulatory cells
CD4+CD25+Foxp3+
AZM
AZM + MTX
Day -2
Day 1
Day 7
5th AZM cycle



Spleen - T cells
CD8 Naive
CD8 CEN
CD8 EFF MEM
CD4 naivee
CD4 CEN MEM
CD4 EFF MEM
AZM
AZM + MTX
Day -2
Day 1
Day 7
5th AZM cycle

FIG. 27A




FIG. 27B




FIG. 28A




FIG. 28B




FIG. 29A




FIG. 29B




FIG. 30A



Bi-weekly Eyebleeds
Alemtuzumab
5 daily doses
0.5 mg/ kg/day
Methotrexate
8 daily doses
2mg/kg/day
1
2
3
4
Months
Day 125
Terminal Sacrifice

FIG. 30B



INFg
GM-CSF
IL-1b
IL-2
IL-4
IL-5
IL-6
IL-7
IL-10
IL-12
IL-13
MCP-1
TNF-a
Conc, pg / ml
PBS
AZM
AZM+MTX (0.5)
AZM+MTX (1.0)
AZM+MTX (2.0)

FIG. 31



Assessment of the effect ofmethotrexate on anti-Myozyme titers inIL10-/- and C57Bl/6 WT
Week 4
Week 6
Week 9
rhGAA titer(n=8)
500000
400000
300000
200000
100000
100000
80000
60000
40000
20000
0
IL10-/-rhGAA
IL10-/-rhGAA+MTX
C57Bl/6rhGAA
C57Bl/6rhGAA+MTX
IL10-/-rhGAA
IL10-/-rhGAA+MTX
C57Bl/6rhGAA
C57Bl/6rhGAA+MTX
IL10-/-rhGAA
IL10-/-rhGAA+MTX
C57Bl/6rhGAA
C57Bl/6rhGAA+MTX

FIG. 32



Follicular B cells
CD19+CD23hiCD21lo
Cells / spleen
40,000,000
30,000,000
20,000,000
10,000,000
0
1 week
2 week
4 week
**
**
B1 Cells
CD19+CD43+CD11b+
Cells / spleen
4,000,000
3,000,000
2,000,000
1,000,000
0
2 week
4 week
***
Marginal zone B cells
CD19+CD23loCD21hi
Cells / spleen
8,000,000
6,000,000
4,000,000
2,000,000
0
1 week
2 week
4 week
Regulatory B cells (B10)
CD19+CD5+CD1d+
Cells / spleen
1,000,000
800,000
600,000
400,000
200,000
0
1 week
2 week
4 week
***
T1 cells
CD19+CD93+IgMhiCD23lo
Cells / spleen
1,200,000
1,000,000
800,000
600,000
400,000
200,000
0
1 week
2 week
4 week
*
T2
CD19+CD93+IgMhiCD23hi
Cells / spleen
600,000
500,000
400,000
300,000
200,000
100,000
0
1 week
2 week
4 week
*
T3
CD19+CD93+IgMloCD23hi
Cells / spleen
1,000,000
750,000
500,000
250,000
0
1 week
2 week
4 week
*

FIG. 33



0
4
64
Day
Alemtuzumab
0.5mg/kg
Methotrexate
3 daily doses
5mg/kg/day
Blood and Spleens for flow. LN for pathological evaluation
Thyroid and LN for pathological evaluation

FIG. 34



B cells
CD19+
Cell number/ ul
10000
5000
0
*
*
MTX
AZM
AZM+MTX
Regulatory B cells (B10)
CD19+CD5+CD1d+
Cell number/ ul
ns
ns
MTX
AZM
AZM+MTX
Activated B10 cells
CD19+CD5+CD1d+CD86+
Cell number/ ul
25
20
15
10
5
0
ns
ns
MTX
AZM
AZM+MTX
B1 Cells
CD19+CD43+CD11b+
Cell number/ ul
250
200
150
100
50
0
ns
ns
MTX
AZM
AZM+MTX
Follicular B cells
CD19+CD23hiCD21lo
Cell number/ ul
15000
10000
5000
0
***
***
MTX
AZM
AZM+MTX
Marginal zone B cells
CD19+CD23loCD21hi
Cell number/ ul
2000
1000
0
**
**
*
MTX
AZM
AZM+MTX

FIG. 35



Total B cells
CD19+
Cell number/ ul
AZM
AZM + MTX
Day -2
Day 1
Day 28
5th AZM cycle
B1 cells
CD19+CD43+CD11b+
Follicular cells
CD19+CD23hiCD21lo
*
Marginal zone B cells
CD19+CD23loCD21hi
Regulatory B cells (B10)
CD19+CD5+CD1d+
Activated B10
CD19+CD5+CD1d+CD86+

FIG. 36



MCP-1
pg/ml
25
20
15
10
5
0
AZM
AZM MTX
AZM
AZM MTX
Pre 5th dose
Post 5th dose
IL13
pg/ml
100
80
60
40
20
0
AZM
AZM MTX
AZM
AZM MTX
Pre 5th dose
Post 5th dose
IL-6
pg/ml
100
80
60
40
20
0
AZM
AZM MTX
AZM
AZM MTX
Pre 5th dose
Post 5th dose
IL-12
pg/ml
250
200
150
100
50
0
AZM
AZM MTX
AZM
AZM MTX
Pre 5th dose
Post 5th dose

FIG. 37A




FIG. 37B





Figure 38A


11.22%
B10
8.24%
63.73%
16.81%
CD1d-PB
CD5-APC
10^0
10^1
10^2
10^3
10^4



87.57%
12.43%
0.00%
0.00%
CD1d-PB
IL10-PE
rhGAA
10^0
10^1
10^2
10^3
10^4

Figure 38A, cont'd




Figure 38B




Figure 39A




Figure 39B




Figure 39B, cont'd





Figure 40A


TGFb+B10
Cell number/cultured well
1000
800
600
400
200
0
p=3.04x10-7
rhGAA
rhGAA+newMTX



rhGAA
CD1d-PB
TGFb-PE
85.80 %
14.20 %
0.00 %
0.00 %
10^0
10^1
10^2
10^3
10^4

Figure 40A, cont'd




Figure 40B



B10 CD86+TGFb+
CD1d-PB
300
200
100
0
p=1.37X10-5
rhGAA
CD86+
TGFb+
rhGAA+MTX
CD86+
TGFb+
B10 CD86negTGFb+
Cell number/cultured well
1000
800
600
400
200
0
p=1.6x10-7
rhGAA
CD86-
TGFb+
rhGAA+MTX
CD86-
TGFb+

Figure 41A



B10 gated through the CD19+ gate
9.67%
4.31%
73.55%
12.47%
CD1d-PB
CD5-APC
FoxP3+ gated through the B10 gate
47.07%
52.93%
0.00%
0.00%
CD1d-PB
FoxP3-PE

Figure 41A, cont'd




Figure 41B



B10 gated through the CD19+ gate
11.18%
5.93
69.58%
13.31
CD1d-PB
CD5-APC
FoxP3+ gated through the B10 gate
31.56%
68.44%
0.00%
0.00%
CD1d-PB
FoxP3-PE

Figure 41B, cont'd




Figure 41C



FoxP3+B10
Cell number/cultured well
3000
2000
1000
0
p=2.2x10-6
rhGAA
rhGAA+MTX
CD86+FoxP3+B10
Cell number/cultured well
1000
800
600
400
200
0
p=0.001
rhGAA
rhGAA+MTX

Figure 41C, cont'd




Figure 42A



Follicular B cells
93.87%
6.13%
0.00%
0.00%
CD23-FITC
IL10-PE
Transitional 2 B cells
34.06%
65.94%
0.00%
0.00%
CD23-FITC
IL10-PE

Figure 42A, cont'd




Figure 42B



Follicular B cells
83.63 %
16.37 %
0.00 %
0.00 %
CD23-FITC
IL10-PE
Transitional 2 B cells
21.71 %
78.29 %
0.00 %
0.00 %
CD23-FITC
IL10-PE

Figure 42B, cont'd




Figure 42C



Total Follicular IL10+ B cells
Cell number/cultured well
2000
1500
1000
500
0
p =1.73x10 -6
rhGAA
IL-10+
rhGAA+MTX
IL-10+
Transitional 2 IL10 + B cells
Cell number/cultured well
800
600
400
200
0
p =0.001
rhGAA
IL-10+
rhGAA+MTX
IL-10+

Figure 42C, cont'd




Figure 43A



Follicular B cells
88.34%
11.66%
0.00%
0.00%
CD23-FITC
TGFb-PE
Traditional 2 B cells
72.33 %
27.67 %
0.00 %
0.00 %
CD23-FITC
TGFb-PE

Figure 43A, cont'd




Figure 43B



88.80%
11.20%
0.00%
0.00%
CD23-FITC
TGFb-PE
50.02%
49.98%
0.00%
0.00%
CD23-FITC
TGFb-PE

Figure 43B, cont'd





Figure 43C


Intracellular TGFβ+ Follicular B cells
Cell number/cultured well
2500
2000
1500
1000
500
0
p=1.4x10 -6
rhGAA
rhGAA+MTX



Total TGFβ+ Transitional 2 B cells
Cell number/cultured well
4000
3000
2000
1000
0
p=2.8x10-7
rhGAA
rhGAA+MTX

Figure 43C, cont'd





Figure 44A

Follicular B cells



Transitional 2 B cells




Figure 44A, cont'd





Figure 44B


89.24%
10.76%
0.00%
0.00%
CD23-FITC
FoxP3-PE



23.21%
76.79 %
0.00%
0.00%
CD23-FITC
FoxP3-PE

Figure 44B, cont'd





Figure 44C


FoxP3+ Follicular cells
Cell number/cultured well
5000
4000
3000
2000
1000
0
p=3x10-5
rhGAA
rhGAA+MTX



FoxP3+ transitional 2 B cells
Cell number/cultured well
1000
800
600
400
200
0
p=2x10 -6
rhGAA
rhGAA+MTX

Figure 44C, cont'd




Figure 45



week 6
Anti-rhGAA titer (n=10)
60000
50000
40000
30000
20000
20000
15000
10000
5000
0
rhGAA
rhGAA+MTX
rhGAA+MTX+1D11
rhGAA+MTX+13C4

Figure 46A




Figure 46B




Figure 46C



FoxP3+ B10
Cell number/cultured well
800
700
600
500
400
300
p =0.01
1D11
MTX
rhGAA
isotype(13C4)
MTX
rhGAA

Figure 47A




Figure 47B




Figure 47C



FoxP3+ Follicular B cells
Cell number/cultured well
1500
1000
500
0
p=0.11
1D11
MTX
rhGAA
isotype(13C4)
MTX
rhGAA

Figure 48A




Figure 48B





Figure 48B, cont'd







Figure 48C


FoxP3+Transitional 2
Cell number/cultured well
800
600
400
200
0
1D11
MTX
rhGAA
isotype(13C4)
MTX
rhGAA



CD86+FoxP3+Transitional 2
Cell number/cultured well
600
400
200
0
p=0.03
1D11
MTX
rhGAA
isotype(13C4)
MTX
rhGAA

Figure 48C, cont'd





Figure 49A


TGFβ+ Transitional 3 cells
Cell number/cultured well
600
500
400
300
200
1D11
MTX
rhGAA
isotype(13C4)
MTX
rhGAA



CD23-FITC
82.42 %
17.58 %
0.00 %
0.00 %
TGFb-PE

Figure 49A, cont'd




Figure 49B





Figure 49B, cont'd







Figure 49C


FoxP3+Transitional 3
Cell number/cultured well
300
200
100
0
1D11
MTX
rhGAA
isotype(13C4)
MTX
rhGAA



CD86 +FoxP3+Transitional 3
Cell number/cultured well
140
130
120
110
100
90
1D11
MTX
rhGAA
isotype(13C4)
MTX
rhGAA

Figure 49C, cont'd





Figure 50A


94.13 %
5.87%
0.00%
0.00%
CD23-FITC
IL10-PE



73.33%
26.67 %
0.00 %
0.00 %
CD23-FITC
IL10-PE

Figure 50A, cont'd




Figure 50B





Figure 50B, cont'd






Figure 50C



97.95%
2.05 %
0.00 %
0.00 %
CD23-FITC
FoxP3-PE
91.61%
8.39%
0.00%
0.00%
CD23-FITC
FoxP3-PE

Figure 50C, cont'd




Figure 51A




Figure 51B




Figure 52





BLOOD
CD4+ T Cells
Total Cells (x10⁶)
1.5
1.0
0.5
0.0
**
0
10
20
30
40
50
Days
CD8+ T Cells
Total Cells (x10⁶)
1.0
0.8
0.6
0.4
0.2
0.0
***
*
0
10
20
30
40
50
Days
CD19+ B Cells
Total Cells (x10⁶)
8
6
4
2
0
0
10
20
30
40
50
Days
rbIgG
mATG
rbIgG + MTX
mATG + MTX

Figure 52, cont'd

SPLEEN








Figure 53




Splenic CD4+ T Cells
14 Days Post Transplant
Total cells (1 x 10^6)
40
35
30
25
20
15
10
5
0
**
**
syngeneic
no treat day 7
MTX
mATG
mATG+MTX
Allo Tx
Splenic CD8+ T Cells
14 Days Post Transplant
Total cells (1 x 10^6)
20
15
10
5
0
**
**
syngeneic
no treat day 7
MTX
mATG
mATG+MTX
Allo Tx

Figure 53, cont'd







Figure 54


B10-IL10_MFI
Mean Fluorescent Intensity (MFI)
p=1.4x10-5
4
3
2
1
0
rhGAA
rhGAA+MTX




nonB10 B cells-IL10_MFI
Mean Fluorescent Intensity (MFI)
p=6.15x10-5
2.0
1.8
1.6
1.4
1.2
1.0
rhGAA
rhGAA+MTX

Figure 55


TGFb+Follicular cells_MFI
Mean Fluorescent Intensity (MFI)
8
7
6
5
4
p=1.5x10 -6
rhGAA
rhGAA+MTX



TGFb+Transitional 2_MFI
Mean Fluorescent Intensity (MFI)
75
70
65
60
55
50
45
p=4.59x10 -4
rhGAA
rhGAA+MTX

Figure 55, cont'd




Figure 56



FoxP3+Follicular MFI
Mean Fluorescent Intensity (MFI)
3.5
3.0
2.5
2.0
p=5.39x10-6
rhGAA
rhGAA+MTX
FoxP3+Transitional 2MFI
Mean Fluorescent Intensity (MFI)
60
55
50
45
40
35
p=4x10-5
rhGAA
rhGAA+MTX

Figure 56, cont'd

